Clinical trial
MK0457 in Patients With Leukemia (0457-003)
NCT00111683 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00111683 |
|---|---|
| Title | MK0457 in Patients With Leukemia (0457-003) |
| Official title | A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia in Blast Crisis, Lymphocytic Leukemia, B Cell, Acute, Myelodysplastic Syndromes, Myelogenous Leukemia, Chronic |
| Intervention type | Drug |
| Interventions | MK0457 |
| Enrollment | 28 |
| Start date | Jun 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | May 25, 2005 |
| Last update posted | Aug 25, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: